健择、卡铂联合治疗非小细胞肺癌的临床疗效  

The clinical study of gemcitabine and carboplatin on non-small-cell lung cancer patients.

作　　者：许真[1] 严丽[1] 陈玲[1] 寇长元[1] 崔杰[1] 

机构地区：[1]陕西省安康市中心医院肿瘤科,陕西安康725000

出　　处：《现代肿瘤医学》2004年第2期133-134,共2页Journal of Modern Oncology

摘　　要：目的　观察健择、卡铂联合治疗非小细胞肺癌的疗效和毒性。方法　对 5 0例Ⅲb～Ⅳ期非小细胞肺癌患者采用随机、双盲方法分为治疗组 2 5例 ,对照组 2 5例 ,治疗组采用健择 10 0 0mg/m2 第 1、8天静脉滴注 ,卡铂 30 0mg/m2 第 1天静脉滴注 ,4周为一周期 ;对照组足叶乙甙 0 .1/m2 第 1、2、3天静脉滴注 ,卡铂30 0mg/m2 第 1天静脉滴注 ,3周为 1周期 ;2周期后评价疗效。结果　治疗组 2 5例可评价疗效 ,完全缓解 6例 ,部分缓解 8例 ,总有效率 5 6 % ,中位缓解期 3.8月 ;对照组 2 5例可评价疗效 ,完全缓解 2例 ,部分缓解 7例 ,有效率 36 %。结论　健择。Objective To observe the effect and toxicity of gemcitabine and carboplatin on non-small cell lung cancer patients.Methods Fifty Ⅲb-Ⅳ grade non-small cell lung cancer patients were divided randomly and double-blind method into control group including 25 patients and therapy group including 25patients.For therapy group,gemcitabine was used by 1000mg/m 2 vein drip at 1st and 8th day,carboplatin was used by 300mg/m 2 at 1st day, 4 weeks was a cycle; for control group,etoplside was used by 0.1/m 2 vein drit at 1st,2nd and 3rd day,carboplatin was used by 300mg/m 2 at 1st day,4 weeks was a cycle.After 2 cycles,curative effect was observed.Results In therapy group,6 patients were completely remission and 8 patients were partly remission,effective rate was 56%,middle term of remission was 3.8 months;In control group,2 patients were completely remission and 7 patients were partly remission,effective rate was 36%.Conclusion gemcitabine and carboplatin is a better therapeutic alliance method on non-small cell lung cancer patients. [

关 键 词：健择 卡铂 联合化疗 非小细胞肺癌 临床疗效 毒性反应 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]